BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 15847669)

  • 21. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
    Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABO incompatible stem cell transplantation in children does not influence outcome.
    Helming AM; Brand A; Wolterbeek R; van Tol MJ; Egeler RM; Ball LM
    Pediatr Blood Cancer; 2007 Sep; 49(3):313-7. PubMed ID: 16960869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
    Armistead PM; Mohseni M; Gerwin R; Walsh EC; Iravani M; Chahardouli B; Rostami S; Zhang W; Neuberg D; Rioux J; Ghavamzadeh A; Ritz J; Antin JH; Wu CJ
    Exp Hematol; 2008 Sep; 36(9):1205-15. PubMed ID: 18550258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylactic red blood cell exchange for ABO-mismatched hematopoietic progenitor cell transplants.
    Cunard R; Marquez II; Ball ED; Nelson CL; Corringham S; Clopton P; Sanchez AP; Lane T; Ward DM
    Transfusion; 2014 Jul; 54(7):1857-63. PubMed ID: 24372185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
    Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
    Baker KS; Loberiza FR; Yu H; Cairo MS; Bolwell BJ; Bujan-Boza WA; Camitta BM; Garcia JJ; Ho WG; Liesveld JL; Maharaj D; Marks DI; Schultz KR; Wiernik P; Zander AR; Horowitz MM; Keating A; Weisdorf DJ
    J Clin Oncol; 2005 Oct; 23(28):7032-42. PubMed ID: 16145067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning.
    Worel N; Böhm A; Rabitsch W; Leitner G; Mitterbauer M; Kalhs P; Mayr WR; Schwartz D; Greinix HT
    Transfusion; 2012 Jun; 52(6):1348-53. PubMed ID: 22128859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
    Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
    Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.